Everolimus-eluting stent (EES) improves long-term prognosis in patients with acute coronary syndrome (ACS) and is currently recommended over bare metal stent (BMS) in this population. Nevertheless, predictors of long-term outcomes in ACS patients treated with EES have not been evaluated in routine practice.

We retrospectively included patients treated with EES for ACS between June 2012 and December 2013 in our institution. Baseline clinical, biological and procedural characteristics were collected and all patients completed at least one-year follow-up. The primary endpoint was defined as the composite of target-vessel revascularization (TVR), target-vessel myocardial infarction (MI), or cardiac death at one year.

of 447 patients included, 67 patients (15.1%) reached the primary endpoint at one year. In a multivariate analysis using Cox regression model, cardiogenic shock (HR 6.74; 95% CI [5-18.6]; p<0,001), baseline anemia, defined by hemoglobin <11g/dL (HR 2.59; 95% CI [1.5-4.5], p=0.002), history of coronary artery bypass surgery (HR 2.21; 95% CI [1.1-11.9], p=0,003) and age (HR 1.04; 95% CI [1.02-1.06], p<0.001) were independent predictors of adverse outcomes at 1 year.

in ACS patients treated with EES, cardiogenic shock and baseline anemia were the most robust predictors of long-term adverse clinical outcomes.

The author hereby declares no conflict of interest